Other ·Insufficient evidence ·Reviewed May 2026
Alcohol is not supported by NutriStack. Safety information only.
The bottom line
Evidence rating insufficient. 15 sources indexed (2017–2026), with 65 interaction records on file.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Not recommended / non-supplement.
No effective supplement dose exists. Cost is intentionally not modeled for this recreational substance. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
Alcohol is not a nutrient supplement and has no diet-first equivalent for wellness dosing.
What to test, the optimal window inside the conventional range, and how long a response takes.
Chronic alcohol intake (above 2 drinks per day) raises GGT; reduction or abstinence lowers GGT with a half-life of about 2 to 3 weeks.7,10
CDT (carbohydrate-deficient transferrin) is more specific for chronic heavy use. AST/ALT ratio above 2 suggests alcoholic hepatitis. PEth (phosphatidylethanol) is the most sensitive recent-use marker.
Chronic heavy alcohol intake is expected to raise AST (often above ALT), while reducing or stopping alcohol lowers it, with the size and speed of change depending on baseline liver status and how much intake is cut.7,10
No fasting strictly required, but avoid alcohol for at least 48 to 72 hours before the draw to avoid acute spikes. An AST to ALT ratio above 2 raises suspicion for alcohol-related liver injury. Retest after a sustained reduction period.
ALDH2 and ADH1B variants substantially change acetaldehyde concentrations after alcohol exposure (PMID 19164089).
Recommendation: Known ALDH2 reduced-function status should be treated as a strong reason to minimize or avoid alcohol rather than using supplements to offset exposure.
Chronic alcohol intake depletes thiamine (B1) and impairs its absorption and activation, raising the risk of Wernicke encephalopathy and Korsakoff syndrome.
Recommendation: Do not treat alcohol use as safe. If alcohol is consumed regularly, arrange thiamine repletion under medical supervision, and seek medical advice for any neurological symptoms.
Milk thistle (silymarin) is often taken for liver support during alcohol use, but evidence does not show it prevents alcohol-related liver damage, and its perceived protection may encourage continued drinking.
Recommendation: Do not treat milk thistle as protection that makes drinking safe. The most effective step for alcohol liver injury is reducing or stopping alcohol; seek medical advice.
Combining alcohol with melatonin can increase sedation and drowsiness, while alcohol itself disrupts the body's natural melatonin rhythm and overall sleep quality.
Recommendation: Do not combine alcohol with melatonin, especially before driving or operating machinery. Avoid alcohol if you are using melatonin for sleep.
Combining THC-dominant cannabis with alcohol produces additive central nervous system depression and impairment, with greater sedation, dizziness, nausea, and markedly worse psychomotor and driving performance than either alone.
Recommendation: Do not combine. The mix sharply increases impairment and accident risk; do not drive or operate machinery, and seek medical advice if severe vomiting, confusion, or loss of consciousness occurs.
Combining cocaine with alcohol produces cocaethylene in the liver, a longer-lasting and more cardiotoxic compound that sharply increases the risk of heart attack, arrhythmia, and sudden death.
Recommendation: Do not combine. This is a dangerous combination associated with sudden cardiac death. If experiencing chest pain, severe agitation, or breathing difficulty, seek emergency medical care immediately.
Combining ketamine with alcohol produces additive central nervous system and respiratory depression, raising the risk of profound sedation, airway compromise, vomiting with aspiration, and loss of consciousness.
Recommendation: Do not combine. If both have been taken together and breathing is slow or shallow, consciousness is impaired, or vomiting occurs, seek emergency medical care immediately.
Combining MDMA with alcohol increases dehydration, cardiovascular strain, and impaired judgment, and alcohol can mask MDMA's perceived effects while worsening next-day impairment and overheating risk.
Recommendation: Do not combine. If overheating, confusion, chest pain, or collapse occurs, seek emergency medical care immediately.
Combining nicotine and alcohol increases cardiovascular strain (heart rate and blood pressure) and reinforces co-dependence, with the two substances mutually increasing consumption and addiction risk.
Recommendation: Do not combine. If you use both, seek medical advice and support for reduction or cessation, since the pairing raises cardiovascular and dependence risks.
Pregnenolone is a neurosteroid that directly opposes GABA-A signaling, yet the body converts much of it into allopregnanolone, which strongly enhances GABA-A signaling the same way alcohol does. So combining pregnenolone with alcohol can swing in either direction: it may blunt the expected buzz/sedation in some people, or it may amplify drowsiness, impaired coordination and slowed reaction time in others (particularly as allopregnanolone levels build). This makes the level of impairment from a given amount of alcohol harder to predict, which is the real-world hazard.
Recommendation: Do not rely on pregnenolone to make alcohol feel less impairing; the metabolite allopregnanolone can do the opposite and deepen sedation. Avoid drinking on the same day you take pregnenolone, and never drive or operate machinery after combining them. If you do take pregnenolone, dose it in the morning and keep alcohol intake minimal and well separated (ideally avoid alcohol within the same dosing day). Use particular caution if you are also taking any sedating supplements or medications.
Amphetamine/dextroamphetamine can partially counter alcohol-related psychomotor slowing without making the person sober. This can make intoxication feel less obvious and encourage more drinking, driving, risky activity, or additional stimulant use. Alcohol and stimulants can also add cardiovascular strain, especially with binge drinking or dehydration.
Recommendation: Avoid alcohol on days you take amphetamine/dextroamphetamine when possible. If you drink, keep intake low, do not drive, and do not take extra stimulant doses to stay alert. Seek care for chest pain, fainting, severe agitation, confusion, or an irregular heartbeat.
Alcohol changes methylphenidate handling and can form ethylphenidate, an active transesterification metabolite. Ethanol can increase early methylphenidate exposure and may intensify euphoria, stimulation, impaired judgment, palpitations, and misuse risk. The combination is especially risky with immediate-release products, high methylphenidate doses, binge drinking, or a history of substance use disorder.
Recommendation: Avoid alcohol while taking methylphenidate, especially around dose times and with immediate-release formulations. Do not drink to intensify methylphenidate or take extra methylphenidate while drinking. Seek care for chest pain, fainting, severe agitation, confusion, or a racing or irregular heartbeat.
Guanfacine lowers sympathetic outflow and commonly causes sedation, fatigue, dizziness, bradycardia, and lower blood pressure. Alcohol can add CNS depression and worsen dizziness, slowed reaction time, orthostatic symptoms, and fainting risk. The combination is most concerning when starting guanfacine, increasing the dose, drinking heavily, or using other sedating substances.
Recommendation: Avoid alcohol when starting guanfacine or after any dose increase. If you drink later in stable treatment, keep intake low and avoid driving, heat exposure, or standing quickly. Seek medical help for fainting, severe dizziness, very slow pulse, confusion, or repeated vomiting.
Numbered references. Citations throughout the page link here.
Islam AH, Alvizuri C, Desalegn H et al.. Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-Analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2026
Gardiner C, Weakley J, Burke LM et al.. The effect of alcohol on subsequent sleep in healthy adults: A systematic review and meta-analysis. Sleep medicine reviews. 2025
Kotake K, Hosokawa T, Tanaka M et al.. Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis. Addiction (Abingdon, England). 2024
Lee CM, Dillon DG, Tahir PM et al.. Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2024
Nelson MJ, Soliman PS, Rhew R et al.. Disruption of circadian rhythms promotes alcohol use: a systematic review. Alcohol and alcoholism (Oxford, Oxfordshire). 2024
de Aguiar ACL, Bloc LG. Transdiagnosis of alcohol use and psychopathologies: A systematic review. Addictive behaviors reports. 2024
Cecchini M, Filippini T, Whelton PK et al.. Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies. Hypertension (Dallas, Tex. : 1979). 2024
Zarezadeh M, Mahmoudinezhad M, Faghfouri AH et al.. Alcohol consumption in relation to cognitive dysfunction and dementia: A systematic review and dose-response meta-analysis of comparative longitudinal studies. Ageing research reviews. 2024
Fiore M, Alfieri A, Torretta G et al.. Dexmedetomidine as Adjunctive Therapy for the Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland). 2024
Meta-analysis of prospective cohorts found a dose-response relationship between alcohol consumption and cancer risk, with elevated risks seen for several cancers even at lower intake levels.
Umar Z, Haseeb Ul Rasool M, Muhammad S et al.. Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Cureus. 2023
Kelson M, Burnett JM, Matthews A et al.. Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. Cureus. 2023
Traccis F, Presciuttini R, Pani PP et al.. Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. Neuroscience and biobehavioral reviews. 2022
Review describes alcohol as a major contributor to preventable morbidity and mortality and summarizes the biologic and clinical drivers of alcohol use disorder.
Review concludes there is strong evidence that alcohol causes cancers of the oropharynx, larynx, esophagus, liver, colon, rectum, and breast.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack